Updated: Jun 23, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Samantha Perspicace1, David Banner, Jörg Benz
1F. Hoffmann-La Roche Ltd, Pharma Research, Discovery Technologies, Basel, Switzerland. samantha.perspicace@unibas.ch
Surface plasmon resonance (SPR) screening successfully identified 80 potential chymase inhibitors from a library of 2226 small molecules. These fragments bind to distinct regions within the enzyme's active site, validated by X-ray crystallography.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: